Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing facility will be ...

Not designing with manufacturing in mind—even during early development—is a key reason fledgling biopharma companies fail.

The latest MES release helps pharmaceutical and biopharmaceutical manufacturers simplify system management and improve ...